Here is an overview of what we consider to be the key website statistics and information:
Parameter name | Status | Comment |
---|---|---|
Website meta title | About GAZYVA® (obinutuzumab) Treatment | Search engines recommend title length of around 50-60 characters. The length of this title is 38. |
Meta description | Learn about GAZYVA® in first-line FL, relapsed/refractory follicular lymphoma, and previously untreated chronic lymphocytic leukemia treatment. Indication: GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment. GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III or IV follicular lymphoma (FL) in adults who have not had previous FL treatment.IMPORTANT SAFETY INFORMATION: What is the most important safety information I should know about GAZYVA? Tell your doctor right away about any side effect you experience. GAZYVA can cause side effects that can become serious or life threatening, including: Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If you have a history of hepatitis B infection, GAZYVA could cause it to return. You should not receive GAZYVA if you have active hepatitis B liver disease. Your doctor or healthcare team will need to screen you for hepatitis B before, and monitor you during and after, your treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes. Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. Your weakened immune system could put you at risk. Your doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems. Who should not receive GAZYVA? Do NOT receive GAZYVA if you have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Tell your healthcare provider if you have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past. What are the additional possible serious side effects of GAZYVA? Tell your doctor right away about any side effect you experience. GAZYVA can cause side effects that may become severe or life threatening, including: Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion reactions. If you have a reaction, the infusion is either slowed or stopped until your symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion reaction is life threatening, the infusion of GAZYVA will be permanently stopped. Your healthcare team will take steps to help lessen any side effects you may have to the infusion process. You may be given medicines to take before each GAZYVA treatment. Symptoms of infusion reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort. Hypersensitivity Reactions Including Serum Sickness: Some people receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, your doctor will stop the infusion and permanently discontinue GAZYVA. Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart, and may lead to kidney failure requiring the need for dialysis treatment. Your doctor may prescribe medication to help prevent TLS. Your doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. Infections: While you’re taking GAZYVA, you may develop infections. Some of these infections may be fatal and severe, so be sure to talk to your doctor if you think you have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. Low White Blood Cell Count: When you have an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While you are taking GAZYVA, your doctor will do blood work to check your white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If your white blood cell count is low, your doctor may prescribe medication to help prevent infections. Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets you have in your blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While you are taking GAZYVA, your doctor will do blood work to check your platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If your platelet count gets too low, your treatment may be delayed or reduced. The most common side effects of GAZYVA in CLL were infusion reactions, low white blood cell counts, low platelet counts, low red blood cell counts, fever, cough, nausea, and diarrhea. The safety of GAZYVA was evaluated based on 392 patients with relapsed or refractory NHL, including FL (81%), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) (a disease for which GAZYVA is not indicated), who did not respond to or progressed within 6 months of treatment with rituximab product or a rituximab product-containing regimen. In patients with follicular lymphoma, the profile of side effects that were seen were consistent with the overall population who had NHL. The most common side effects of GAZYVA were infusion reactions, low white blood cell counts, nausea, fatigue, cough, diarrhea, constipation, fever, low platelet counts, vomiting, upper respiratory tract infection, decreased appetite, joint or muscle pain, sinusitis, low red blood cell counts, general weakness, and urinary tract infection. A randomized, open-label multicenter trial (GALLIUM) evaluated the safety of GAZYVA as compared to rituximab product in 1,385 patients with previously untreated follicular lymphoma (86%) or marginal zone lymphoma (14%). The most common side effects of GAZYVA were infusion reactions, low white blood cell count, upper respiratory tract infection, cough, constipation and diarrhea. What other information should I tell my doctor before receiving GAZYVA? You should talk to your doctor about: Immunizations: Before receiving GAZYVA therapy, tell your healthcare provider if you have recently received or are scheduled to receive a vaccine. People who are treated with GAZYVA should not receive live vaccines. Pregnancy: Tell your doctor if you are pregnant, think that you might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm your unborn baby. Speak to your doctor about using GAZYVA while you are pregnant. Talk to your doctor or your child’s doctor about the safety and timing of live virus vaccinations to your infant if you received GAZYVA during pregnancy. It is not known if GAZYVA may pass into your breast milk. Speak to your doctor about using GAZYVA if you are breastfeeding. Tell your doctor about any side effects. These are not all of the possible side effects of GAZYVA. For more information, ask your doctor or pharmacist. GAZYVA is available by prescription only. You may report side effects to the FDA at (800) FDA-1088, or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the accompanying full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information. | To make sure all the meta description is visible in search results page, Google recommends length of up to 320 characters at the most. This description has exactly 8749 characters. |
Keywords | gazyva, obinutuzumab, genentech, roche, CLL, chronic lymphocytic leukemia, chronic lymphocytic leukemia therapy, CLL treatment, follicular lymphoma treatment, refractory FL, relapsed FL, follicular lymphoma | We did not expect meta keywords to be used. It's a worrying sign more than anything, really, as websites with meta keywords often tend to be spammy. |
Load time | 2.1923 seconds on average | Load speed is a concern and should be improved if and when possible. |
Quantcast global | 756 161 | The website's rank is quite poor. As with Alexa, QUANTCAST is not always perfectly representative of a website's performance. |
Total links on homepage | We found 40 links | This is a normal amount of links. |
Page HTML size | 51.5KB | How do we put this... improvement is quite necessary. Load speed is a very important factor in so many ways! |
Website server | Server appears to be online. The IP address for the server is 52.9.213.7. | It's unfortunate, but despite our best attempts, we failed to gather enough data to provide a meaningful insight at this time. |
What, all that information was not enough? You want... more? Right, then. You asked for it.
QUANTCAST - an advertising-related data processing company - mostly specializes in real-time audience analysis and measurements. In other words it, like Alexa, is basing its rankings on approximate traffic numbers. Currently, QUANTCAST has rated around 172 504 131 websites. Just like ALEXA, this is not a metric of huge importance, so don't base your SEO decisions on QUANTCAST rank, specifically. At best, it's a vague representation of how your website is doing in the grand scheme of things, but it does not take all that much context into account.
Similarly to how a hard drive or a modern SSD device holds your files, a server holds all the files the website needs to operate. To load a webpage, your browser needs to contact the said server and request files - strings of code that make up the website into what it is, including images, text and database entries. Each physical server has a unique IP address that is used by the browser to contact it.
Let's see what technical information we've managed to gather:
Header in detail |
---|
HTTP/1.1 200 OK Accept-Ranges: bytes Content-Type: text/html; charset=UTF-8 Date: Fri, 24 Nov 2017 19:30:42 GMT ETag: "ccbb-55e99a88e7abb" Last-Modified: Wed, 22 Nov 2017 22:15:34 GMT Server: Apache ServerID: web01 Content-Length: 52411 Connection: Close |
WHOIS information |
---|
Whois Server Version 2.0 Domain names in the .com and .net domains can now be registered with many different competing registrars. Go to http://www.internic.net for detailed information. Domain Name: GAZYVA.COM Registrar: SAFENAMES LTD Sponsoring Registrar IANA ID: 447 Whois Server: whois.safenames.net Referral URL: http://www.safenames.net Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Updated Date: 17-oct-2016 Creation Date: 10-nov-2011 Expiration Date: 10-nov-2017 >>> Last update of whois database: Sat, 29 Apr 2017 14:00:21 GMT <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars. Domain Name: GAZYVA.COM Registry Domain ID: 1686469138_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2016-10-17T13:44:57Z Creation Date: 2011-11-10T09:24:17Z Registrar Registration Expiration Date: 2017-11-10T09:24:17Z Registrar: Safenames Ltd Registrar IANA ID: 447 Registrar Abuse Contact Email: Registrar Abuse Contact Phone: +44.1908200022 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Registry Registrant ID: Not Available From Registry Registrant Name: Domain Administrator Registrant Organisation: Genentech, Inc Registrant Street: 1 DNA Way Registrant Street: Registrant City: South San Francisco Registrant State/Province: CA Registrant Postal Code: 94080 Registrant Country: US Registrant Phone: +1.6502257923 Registrant Fax: Registrant Email: Global. Registry Admin ID: Not Available From Registry Admin Name: global. Admin Organisation: F. Hoffmann-La Roche AG Admin Street: Grenzacherstrasse 124 Admin Street: Admin City: Basel Admin State/Province: Basel Admin Postal Code: 4070 Admin Country: CH Admin Phone: +41.55578787 Admin Fax: Admin Email: global. Registry Tech ID: Not Available From Registry Tech Name: International Domain Tech Tech Organisation: International Domain Tech Tech Street: Safenames House, Sunrise Parkway Tech Street: Tech City: Milton Keynes Tech State/Province: Bucks Tech Postal Code: MK14 6LS Tech Country: UK Tech Phone: +44.1908200022 Tech Fax: +44.1908325192 Tech Email: Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM DNSSEC: unsigned URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/ >>> Last update of WHOIS database: 2016-10-17T13:44:57Z <<< "For more information on Whois status codes, please visit https://icann.org/epp" Safenames - Experts in Global Domain Management and Online Brand Protection Domain Registration in over 760 different extensions Enterprise Domain Management since 1999 Mark Protect™ Online Brand Monitoring and Enforcement Domain Consulting and Strategy Domain Name Acquisition Domain Disputes and Recovery Visit Safenames at www.safenames.net +1 703 574 5313 in the US/Canada +44 1908 200022 in Europe The Data in the Safenames Registrar WHOIS database is provided by Safenames for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. Safenames does not guarantee its accuracy. Additionally, the data may not reflect updates to billing contact information. By submitting a WHOIS query, you agree to use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to Safenames (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of Safenames. Safenames reserves the right to terminate your access to the Safenames Registrar WHOIS database in its sole discretion, including without limitation, for excessive querying of the WHOIS database or for failure to otherwise abide by this policy. Safenames reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy. |
A good domain address is usually one that is easy to spell, resulting in the smallest amount of mistypes possible. Still, such a thing inevitably happens. Here is a list with the most frequent 1792 mistypes, associated with gazyva.com:
If you are curious about what TLD extensions could also match the domain name of gazyva.com well, we have prepared an extensive list for you to look through:
We are glad you have finished this report. Hopefully, you found what you were looking for. In case you need more information to compare, here is a list of some other detailed overviews we have prepared: